News & Updates

In Chinese patients with stage N2–3 nasopharyngeal carcinoma (NPC) who have completed concurrent chemoradiotherapy (cCRT), adjuvant cisplatin-gemcitabine significantly improves progression-free survival (PFS) vs current standard of care (SoC) with adjuvant cisplatin-fluorouracil, according to a phase III trial at four cancer centres in China that was reported at ASCO 2023.

The combination of camrelizumab plus apatinib and temozolomide appears to be beneficial in the first-line treatment of advanced acral melanoma, with the majority of the patients showing response and an acceptable safety profile, according to the results of a phase II study.

Female young adult cancer survivors (YACS) with sexual dysfunction show higher levels of fatigue, have worse sleep, and experience more frequent severe pain compared to those without sexual dysfunction, reports a study.

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Low-risk branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) appear to have a positive outlook, with the results of a recent meta-analysis showing that the incidence of advanced neoplasia during extended surveillance is low.

A school-based immunization program in Singapore has resulted in high uptake and coverage of the human papillomavirus (HPV) vaccine, reports a study.